Clinical course of atopic dermatitis after dupilumab discontinuation: a multicentre real-world study
Clinical and Experimental Dermatology · 27.10.2025 · 50 (11) · 2221-2231
DOI: 10.1093/ced/llaf275 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Experimental Dermatology, online erschienen am 20.06.2025. Verfasst von Francesca Barei und 54 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Withholding Treatment. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan, Italian Ministry of Health, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan.
Abstract (Originalsprache)
Background
Limited data exist on the clinical course of atopic dermatitis (AD) after the discontinuation of dupilumab.
Objectives
To assess disease progression following dupilumab discontinuation.
Methods
A multicentre, retrospective study was conducted on 208 patients with severe AD who discontinued dupilumab for reasons unrelated to inefficacy. The Eczema Area and Severity Index (EASI), pruritus numerical rating scale (P-NRS), Atopic Dermatitis Control Tool (ADCT) and Dermatology Life Quality Index (DLQI) were used to assess disease activity after discontinuation. Kaplan–Meier analysis was used to estimate the time and probability of disease worsening (defined as EASI > 7.0, EASI increase ≥ 6.6, P-NRS ≥ 4, P-NRS increase ≥ 4, ADCT ≥ 7, ADCT increase ≥ 5, or DLQI increase ≥ 4), as well as the need to restart systemic treatment.
Results
The main reasons for discontinuing dupilumab were clinical remission or good clinical control (43.3%), patient’s decision (11.1%) and pregnancy or desire to become pregnant (20.7%). Patients with a family history of AD or nonclassical phenotypes had a significantly higher likelihood of disease worsening. A significant portion (42.8%) of patients resumed systemic treatment within a median time of 47 weeks. They had a baseline median EASI score of 10.0 and a median P-NRS of 6.0. The probability of resuming systemic treatment was 25% at 31 weeks and 50% at 94 weeks. Reinitiation of dupilumab significantly improved EASI and P-NRS scores within 16 weeks.
Conclusions
Discontinuing dupilumab is associated with disease recurrence in some patients, especially those with a family history or nonclassical AD. Dupilumab reinitiation is effective, leading to significant clinical improvements and supporting its use after treatment interruption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Unit of Dermatology, University of Parma, Parma, Italy.
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
ORCID-Profile: Francesca Barei, Gianluca Avallone, Luca Stingeni, Luigi Gargiulo
Förderung
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan
- Italian Ministry of Health
- Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan
Zitieren
APA
Barei, F., Macchi, S., Calzari, P., Ribero, S., Ortoncelli, M., Foti, C., Balato, A., Di Brizzi, E. V., Peris, K., Gori, N., Ippoliti, E., Gurioli, C., Piraccini, B. M., Trave, I., Cozzani, E., Pezzolo, E., Bonzano, L., Errichetti, E., Schettini, N., …, & Ferrucci, S. M. (2025). Clinical course of atopic dermatitis after dupilumab discontinuation: a multicentre real-world study. Clinical and Experimental Dermatology, 50(11), 2221-2231. https://doi.org/10.1093/ced/llaf275
Vancouver
Barei F, Macchi S, Calzari P, Ribero S, Ortoncelli M, Foti C, et al. Clinical course of atopic dermatitis after dupilumab discontinuation: a multicentre real-world study. Clinical and Experimental Dermatology. 2025;50(11):2221-2231. doi:10.1093/ced/llaf275
BibTeX
@article{Barei2025,
author = {Barei, Francesca and Macchi, Stefano and Calzari, Paolo and Ribero, Simone and Ortoncelli, Michela and Foti, Caterina and Balato, Anna and Di Brizzi, Eugenia Veronica and Peris, Ketty and Gori, Niccolò and Ippoliti, Elena and Gurioli, Carlotta and Piraccini, Bianca Maria and Trave, Ilaria and Cozzani, Emanuele and Pezzolo, Elena and Bonzano, Laura and Errichetti, Enzo and Schettini, Natale and Nettis, Eustachio and Gola, Massimo and Milanesi, Nicola and Feliciani, Claudio and De Felici Del Giudice, Maria Beatrice and Campanati, Anna and Gioacchini, Helena and Pisapia, Armando and Avallone, Gianluca and Micali, Giuseppe and Musumeci, Maria Letizia and Ortega, Romina and Manzo Margiotta, Flavia and Romanelli, Marco and Hansel, Katharina and Stingeni, Luca and Patruno, Cataldo and Esposito, Maria and Fargnoli, Maria Concetta and De Berardinis, Andrea and Ferreli, Caterina and Calabrese, Laura and Rubegni, Pietro and Lazzeri, Laura and Grigolato, Laura and Galli, Benedetta and Rossi, Mariateresa and Maurelli, Martina and Girolomoni, Giampiero and Lauletta, Giuseppe and Napolitano, Maddalena and Alfano, Angela and Gargiulo, Luigi and Narcisi, Alessandra and Marzano, Angelo Valerio and Ferrucci, Silvia Mariel},
title = {Clinical course of atopic dermatitis after dupilumab discontinuation: a multicentre real-world study},
journal = {Clinical and Experimental Dermatology},
year = {2025},
volume = {50},
number = {11},
pages = {2221--2231},
doi = {10.1093/ced/llaf275}
}
EUVIMED